"Animal chimeras—such as the SCID mouse made by placing human immune cells into a mouse to model human immune disorders—have proved to be invaluable in understanding
biology and disease. However, the step from this to placing human neural tissue into an animal is giving governments pause; many are assessing where the line should be drawn between ethics and benefit to future human therapy."

Objective1: Identify the top three challenges of this issue from the view of industry, patient advocacy and medical research.

Objective2: "Explore how these differing agendas intersect, using actual examples of successfully (or not) managing patient expectations—and lessons learned."

Objective3: View the issue's long-range impact on the drug development process and reputation assigned to industry through a bioethicist's lens, and consider the issue's value as academic research topic.